IT1217303B - Ceppi batterici particolarmente utili per la produzione di vaccini per il trattamenmto di malattie intestinali e simili e metodo di ingegneria gentica per la produzione dei detti vaccini - Google Patents

Ceppi batterici particolarmente utili per la produzione di vaccini per il trattamenmto di malattie intestinali e simili e metodo di ingegneria gentica per la produzione dei detti vaccini

Info

Publication number
IT1217303B
IT1217303B IT8547624A IT4762485A IT1217303B IT 1217303 B IT1217303 B IT 1217303B IT 8547624 A IT8547624 A IT 8547624A IT 4762485 A IT4762485 A IT 4762485A IT 1217303 B IT1217303 B IT 1217303B
Authority
IT
Italy
Prior art keywords
vaccines
production
gentic
intestinal
bacterial
Prior art date
Application number
IT8547624A
Other languages
English (en)
Italian (it)
Other versions
IT8547624A0 (it
Inventor
Paul A Manning
Peter Richard Reeves
Derrick Rowley
Original Assignee
Enterovax Res Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterovax Res Pty Ltd filed Critical Enterovax Res Pty Ltd
Publication of IT8547624A0 publication Critical patent/IT8547624A0/it
Application granted granted Critical
Publication of IT1217303B publication Critical patent/IT1217303B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/107Vibrio
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/848Escherichia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IT8547624A 1984-02-01 1985-01-31 Ceppi batterici particolarmente utili per la produzione di vaccini per il trattamenmto di malattie intestinali e simili e metodo di ingegneria gentica per la produzione dei detti vaccini IT1217303B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPG342384 1984-02-01
AUPG795884 1984-11-02

Publications (2)

Publication Number Publication Date
IT8547624A0 IT8547624A0 (it) 1985-01-31
IT1217303B true IT1217303B (it) 1990-03-22

Family

ID=25642755

Family Applications (1)

Application Number Title Priority Date Filing Date
IT8547624A IT1217303B (it) 1984-02-01 1985-01-31 Ceppi batterici particolarmente utili per la produzione di vaccini per il trattamenmto di malattie intestinali e simili e metodo di ingegneria gentica per la produzione dei detti vaccini

Country Status (6)

Country Link
US (1) US5066596A (da)
EP (1) EP0175699A4 (da)
AU (1) AU589114B2 (da)
DK (1) DK442185A (da)
IT (1) IT1217303B (da)
WO (1) WO1985003521A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650065T2 (de) * 1985-07-31 1995-03-02 Univ Leland Stanford Junior Invasive Mikroorganismen.
EP0251579A3 (en) * 1986-06-24 1989-03-22 Enterovax Research Pty. Ltd. Non-antibiotic marker system
EP0257837A1 (en) * 1986-08-19 1988-03-02 Enterovax Research Pty. Ltd. Hybrid bacterial strain
US5124153A (en) * 1987-08-24 1992-06-23 University Of Tennessee Research Corp. Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
US5162226A (en) * 1987-08-24 1992-11-10 University Of Tennessee Research Corp. (U.T.R.C.) Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
WO1989003427A1 (en) * 1987-10-07 1989-04-20 Washington University A method of maintaining a desired recombinant gene in a genetic population of cells
JPH03501326A (ja) * 1988-06-20 1991-03-28 ルミニス・プロプライアタリー・リミテッド 血清型分類用dnaプローブ
JPH0284172A (ja) * 1988-07-21 1990-03-26 Smithkline Beckman Corp 異種遺伝子の発現能を有し、組換え型ワクチンとして有用なサルモネラ形質転換体
US6043057A (en) * 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
US5149532A (en) * 1989-11-01 1992-09-22 Cedars Sinai Medical Center Method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms
DK0556333T3 (da) * 1990-11-09 2003-07-14 Univ Washington Avirulente Salmonella mikrober, der omfatter en mutation i cdt genet, og anvendelser deraf
US5622670A (en) * 1993-05-14 1997-04-22 Rowley; William Process for fabricating crosslinked polyethylene tubing ends
WO1996000233A1 (en) * 1994-06-24 1996-01-04 Children's Hospital And Medical Center Escherichia coli o157:h7 epithelial adhesin
GR950300072T1 (en) * 1995-10-13 1996-01-31 Schweiz Serum & Impfinst Recombinant live vaccines against Gram-negative enteric pathogens
US6344201B1 (en) * 1998-03-31 2002-02-05 Anthony T. Maurelli Methods of identifying bacterial genes that are incompatible with bacterial pathogenicity, and the use of such genes, such as cadA, to reduce pathogenicity in a bacteria or to combat pathogenic bacterial infections
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US7396822B2 (en) 2001-05-24 2008-07-08 Vaxiion Therapeutics, Inc. Immunogenic minicells and methods of use
GB0212666D0 (en) * 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
WO2005026203A2 (en) * 2003-09-18 2005-03-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna promoters and anthrax vaccines
WO2006055024A2 (en) * 2004-04-05 2006-05-26 Vaxiion Therapeutics, Inc. Minicells as vaccines
WO2007028985A2 (en) * 2005-09-07 2007-03-15 The Secretary Of State For Defence Adjuvanted vaccine
GB2453475B (en) 2006-07-25 2011-01-19 Secr Defence Live vaccine strain
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
US8709444B2 (en) 2009-05-14 2014-04-29 Northwestern University Live-attenuated compositions for bacterial infections
DK2675474T3 (da) 2011-02-15 2019-04-23 Vaxiion Therapeutics Llc Terapeutiske sammensætninger og fremgangsmåder til målrettet administration af bioaktive molekyler ved bak-terielle miniceller baseret på antistof og fc-holdige tar-geting-molekyler
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB209314A (en) * 1923-02-07 1924-01-10 Francis John Cheadle A new or improved horse shoe
US3856935A (en) * 1971-04-29 1974-12-24 Schweiz Serum & Impfinst Oral typhoid vaccine and method of preparing the same
GB1472624A (en) * 1974-09-02 1977-05-04 Canadian Patents Dev Enteric disease vaccine
US4264737A (en) * 1978-09-21 1981-04-28 President And Fellows Of Harvard College Method of making genetically stable mutants of vibrio cholerae
US4328209A (en) * 1979-04-11 1982-05-04 Board Of Regents, The University Of Texas System Cholera vaccine
US4311797A (en) * 1979-09-18 1982-01-19 University Of Saskatchewan Anucleated live E. coli vaccine
IL59663A (en) * 1980-03-19 1983-02-23 Univ Ramot Vaccines obtained from bacterial mutant strains of enterobacteriaceae and pseudomonaceae
GB2094314A (en) * 1981-02-05 1982-09-15 Wellcome Found Recombinant DNA
NZ199866A (en) * 1981-03-09 1984-11-09 Cetus Corp Vaccine for prevention of gastroenteric disease:non-pathogenic strain genetically engineered to comprise genes for adhesin and/or toxoids
US4632830A (en) * 1981-07-31 1986-12-30 The United States Of America As Represented By The Secretary Of The Army Oral vaccine for immunization against enteric disease
CA1338705C (en) * 1981-10-22 1996-11-12 Roy Curtiss Iii Vaccines obtained from antigenic gene products of recombinant genes
EP0084522A3 (de) * 1982-01-18 1983-10-19 Sandoz Ag Neue Plasmide und Bakterienstämme sowie Verfahren zu ihrer Herstellung
JPS58146596A (ja) * 1982-02-25 1983-09-01 Takeda Chem Ind Ltd 組換えdna、それで形質転換させた微生物およびそれらの用途
US4440748A (en) * 1982-04-03 1984-04-03 Merck & Co., Inc. Strain of Escherichia coli by bacterial conjugation
US4666837A (en) * 1982-05-24 1987-05-19 Smithkline-Rit DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits
GB8314645D0 (en) * 1983-05-26 1983-06-29 Wellcome Found Bivalent vaccines

Also Published As

Publication number Publication date
DK442185D0 (da) 1985-09-30
DK442185A (da) 1985-11-29
EP0175699A4 (en) 1988-06-13
WO1985003521A1 (en) 1985-08-15
US5066596A (en) 1991-11-19
IT8547624A0 (it) 1985-01-31
AU589114B2 (en) 1989-10-05
EP0175699A1 (en) 1986-04-02
AU3890085A (en) 1985-08-27

Similar Documents

Publication Publication Date Title
IT1217303B (it) Ceppi batterici particolarmente utili per la produzione di vaccini per il trattamenmto di malattie intestinali e simili e metodo di ingegneria gentica per la produzione dei detti vaccini
IT1223709B (it) Anelli terapeutici e procedimento per la loro produzione
ES2025255B3 (es) Metodo para la produccion de 1 - olefinpolimeros
FR2635645B1 (fr) Machine et procede de fabrication combinee de pain et de yaourt
NL193218B (nl) Werkwijze voor de bereiding van roestvrij staal.
ES546654A0 (es) Metodo de produccion de factor viii:c humano
IS1571B (is) Aðferð til framleiðslu á afleiðum tetralíns, cromans og skyldra efnasambanda til meðferðar á asma, liðagigt og skyldum sjúkdómum
IT1219084B (it) Procedimento per la fabbricazione di cemento
IT1148618B (it) Procedimento enzimatico per la produzione di acido 3-indolpiruvico e utilizzazione farmaceutica di questo
IT8220038A0 (it) Preparazione di insulina stabilizzate e metodo per la loro produzione.
DK37590D0 (da) Undersoegelsesmetode for 1,25-dihydroxy vitamin d
MX156304A (es) Metodo mejorado para la produccion de clinquer de cemento
ES552935A0 (es) Procedimiento para la produccion de d-l-amino acidos
IT1190177B (it) Metodo per la produzione di materiali-fibrosi-non tessuti,elasticizzati e relativi prodotti
MX156303A (es) Metodo mejorado para la produccion de clinquer de cemento
IT1187681B (it) Metodo per la preparazione di 3,4-epossibutirrati alchilici
IT8420926A0 (it) Dispositivo per la produzione diprodotti di pasticceria arrotolati morbidi come brioches, cornetti e simili.
FI885914A (fi) Kokolihasta muotoiltujen tuotteiden valmistusmenetelmä
IT8609432A0 (it) Metodo per la produzione di sbarramenti di contenimento di contaminati e simili.
ES552205A0 (es) Metodo para la fabricacion de calzado
IT1226587B (it) Metodo per la produzione di veratrale e di altri alchil-aril-eteri similari
IT8249656A0 (it) Preparato anti-infiammatorio nonsteroideo, per il trattamento delle affezioni artroreumatiche e metodo per la sua preparazione
IT8719490A0 (it) Procedimento per la produzione continua di isoftalodinitrile.
IT1209508B (it) Nuovi medicinali per il trattamento di malattie cardiache.
IT8222835A0 (it) Isoneri di amminoacidi eprocedimento per la loro produzione.